Ophthalmology
Page 1 • 8 itemsGain critical insights into global ophthalmology drug development, market trends, and regulatory landscapes. Inform your pharma investment and BD strategy.
Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science
Everads Therapy reports favorable safety and tolerability data for its novel suprachoroidal drug delivery device in first-in-human trial published in peer-reviewed journal.
Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026
Spinogenix presents preclinical data showing Tazbentetol (SPG302) reduces retinal cell loss and preserves visual function in eye disease models at ARVO 2026.
Restore Vision Reports Positive Safety Data for RV-001 Gene Therapy in Retinitis Pigmentosa Trial
Restore Vision's RV-001 optogenetic gene therapy shows no dose-limiting toxicities in Phase I/II trial for advanced retinitis pigmentosa patients at 168 days.
Oculis to Present DME Research and Pipeline Updates at ARVO 2026 Annual Meeting
Oculis will present findings from DME AWARE Delphi Study highlighting unmet needs in diabetic macular edema treatment at ARVO 2026 meeting.
Ashvattha Therapeutics Presents Migaldendranib Data for Diabetic Macular Edema and AMD Treatment
Ashvattha Therapeutics announces presentations on Migaldendranib's mechanism of action for treating diabetic macular edema and neovascular AMD via subcutaneous delivery.
Outlook Therapeutics Completes FDA Dispute Resolution Meeting for LYTENAVA Bevacizumab Biosimilar
Outlook Therapeutics completed Federal Dispute Resolution meeting with FDA for ONS-5010/LYTENAVA bevacizumab-vikg retinal disease treatment regulatory pathway.
LENZ Therapeutics Submits VIZZ Presbyopia Treatment for UK Approval Following EU Validation
LENZ Therapeutics submits VIZZ aceclidine eye drops to UK MHRA for presbyopia treatment approval, following successful EU regulatory validation in March 2026.
Glaukos Receives Permanent J-Code J2789 for Epioxa™ Ophthalmic Treatment, Effective July 2026
Glaukos Corporation secures permanent HCPCS J-code J2789 for Epioxa™ from CMS, streamlining Medicare reimbursement for ophthalmic treatments starting July 2026.